Preclinical Evaluation of D-2-Hydroxyglutarate Inhibitor to Target Glioblastoma

The brain is a complex organ where cells must follow strict rules to grow and function. When these rules break down, a type of aggressive cancer called glioblastoma can take hold. This disease is notorious for its speed and its ability to resist standard treatments like surgery and radiation, leaving patients with very few options for long-term survival. A key part of the problem lies in a specific enzyme, a protein that normally helps cells manage their energy. In many cases of this brain cancer, this enzyme becomes mutated, or changed. Instead of performing its usual job, the broken enzyme starts producing a harmful substance known as a "oncometabolite." This substance acts like a fuel for the tumor, helping it grow and making it harder to treat. Scientists have long suspected that if they could stop this harmful substance from being made, they might be able to slow or stop the cancer itself.

Researchers at the Manipal Academy of Higher Education in India set out to find a new way to block this process. They began by using computer simulations to screen thousands of potential chemical compounds, looking for one that could specifically target the mutated enzyme and stop it from creating the harmful substance. From this digital search, they selected a new chemical entity, a molecule that had been shortlisted from a database for this specific target, to see if it could work in living systems. They compared this new candidate against an existing drug known as vorasidenib, which is currently undergoing clinical development for low-grade gliomas. The team wanted to see if their new molecule could kill cancer cells in a dish and, more importantly, if it could reduce tumor growth and lower the levels of the harmful substance inside the brains of living animals.

To test their ideas, the scientists first worked with cancer cells grown in a laboratory. They exposed both human and rat brain cancer cells to different amounts of the new molecule and the standard drug. They found that both substances were able to kill the cancer cells, with the new molecule showing a strong ability to stop the cells from surviving. The researchers calculated the specific amount needed to kill half of the cells, finding that the new molecule was effective at a concentration of roughly 720 micromolar, a figure very close to that of the standard drug. This initial success suggested that the new molecule was a potent candidate for further testing.

The study then moved to living animals, using female rats that had been given brain tumors to mimic the human disease. The animals were divided into groups: some received no treatment, some received a harmless fluid, some received the standard drug, and others received the new molecule. The researchers administered the treatments orally for a week. They observed that the animals treated with either the standard drug or the new molecule maintained their body weight better than the untreated sick animals, indicating that the treatments were helping the animals stay healthy. More critically, when the researchers measured the levels of the harmful substance in the blood and brain tissue of the rats, they found a dramatic difference. In the untreated animals, the harmful substance was present at high levels, exceeding 100 nanograms per gram of tissue. In the animals treated with the new molecule, this level dropped significantly to below 50 nanograms per gram, matching the reduction seen in the group treated with the standard drug.

The team also looked at the actual brain tissue under a microscope to see what was happening inside the tumors. In the untreated animals, the tissue showed clear signs of aggressive cancer, including rapid cell division and abnormal cell shapes. In the animals treated with the new molecule, these signs of cancer were largely gone. The researchers noted that the new treatment successfully stopped the cancer cells from multiplying and reduced the presence of a specific marker, known as Ki67, which indicates how fast cells are dividing. By the end of the treatment period, the brain tissue in the treated animals showed complete eradication of tumor cell proliferation, necrosis, and vascular proliferation, although moderate to severe expression of macrophages was still observed at 16 and 24 hours.

While the study showed promising results, the researchers were careful to note that the new molecule behaved differently than the standard drug in terms of how much of it was found in the blood versus the brain. The new molecule reached higher levels in the blood but lower levels in the brain compared to the standard drug, yet both achieved the same result of lowering the harmful substance. This suggests that the new molecule is very effective at its job, even if it travels through the body in a different way. The authors conclude that this new chemical entity has significant potential to treat this aggressive brain cancer by targeting the root cause of the tumor's growth. They suggest that while the current results are strong, future studies will need to look deeper into how the drug moves through the body and how it affects the disease at a molecular level to fully understand its potential as a therapy.